Key Findings:  Targeting the CB1 and CB1 receptors, the symptomatic and therapeutic effects of cannabis, such as decreased gut motility, secretions, and reduced inflammatory edema, may help in inflammatory bowel disorders. But because of the small sample sizes, it is difficult to draw firm conclusions about the safety and efficacy. Larger and better-controlled sample sizes and standardized compositions of cannabis products are needed.
Type of Study:  Meta-analysis
Study Result:  Positive
Research Location(s):  Pakistan, United Kingdom, United States
Year of Pub:  2024
Cannabinoids Studied:  Cannabinoid (unspecified), Endocannabinoid (unspecified)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  CB1, CB2, GPCR
Citation:  Rauf A, Nisar M, Shaeel M, Athar A, Rehman MMU, Faheem F. The Potential of Cannabis in Managing Inflammatory Bowel Disease and Its Future Perspective. Cureus. 2024 Oct 8;16(10):e71068. doi: 10.7759/cureus.71068. PMID: 39624503; PMCID: PMC11610528.